David A. Spiegel, BS’85, MD’90, HS’90-’96, has been named the recipient of the 2026 Humanitarian Award by the Duke Medical Alumni Association in recognition of his extraordinary global impact and commitment to advancing pediatric orthopaedic care.

Danny Benjamin, MD, HS’98-’01, PhD, has been named a recipient of a 2026 Distinguished Faculty Award by the Duke Medical Alumni Association in recognition of his transformative leadership in pediatric clinical research, his national impact on child health, and his deep commitment to mentoring the next generation of investigators.

Ronald N. Goldberg, MD, has been named a recipient of a 2026 Honorary Alumni Award by the Duke Medical Alumni Association in recognition of his transformative impact on neonatal/perinatal medicine and his longstanding commitment to improving outcomes for critically ill newborns.

Durga S. Borkar, MD, MMCi’21, has been named a recipient of a 2026 Emerging Leader Award by the Duke Medical Alumni Association in recognition of her exceptional impact at the intersection of vitreoretinal surgery, clinical data science, and health‑technology innovation.

Kathryn M. Andolsek, MD, HS’76-’79, has been named the recipient of a 2026 Distinguished Faculty Award by the Duke Medical Alumni Association in recognition of her transformative contributions to medical education, community health, and institutional leadership.

Researchers led by Duke Health have reached a major milestone in a national effort to develop a new treatment aimed at helping the body repair damaged joints at the source, accelerating momentum toward a potential commercially available therapy.

Study shows an experimental anti‑inflammatory drug was safe in older surgery patients and may reduce postoperative delirium.

Researchers at Duke University School of Medicine are investigating a potential biomarker to better detect and monitor central nervous system (CNS) involvement in Pompe disease, a metabolic disorder that leads to muscle weakness, respiratory failure, and heart problems. 

A newly published study from Duke Cancer Institute researchers sheds light on a long‑standing mystery in cancer biology and reveals a potential new path toward more targeted treatments for pancreatic and other solid tumors.